These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7490368)

  • 1. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis.
    Kikuchi K; Kubo M; Sato S; Fujimoto M; Tamaki K
    J Am Acad Dermatol; 1995 Dec; 33(6):973-8. PubMed ID: 7490368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.
    Yazawa N; Kikuchi K; Ihn H; Fujimoto M; Kubo M; Tamaki T; Tamaki K
    J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):70-5. PubMed ID: 10607322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts.
    Kikuchi K; Kadono T; Furue M; Tamaki K
    J Invest Dermatol; 1997 Mar; 108(3):281-4. PubMed ID: 9036925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
    Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
    Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis.
    Kikuchi K; Kubo M; Hoashi T; Tamaki K
    Clin Exp Dermatol; 2002 Jun; 27(4):301-5. PubMed ID: 12139676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Sato S; Nagaoka T; Hasegawa M; Tamatani T; Nakanishi T; Takigawa M; Takehara K
    J Rheumatol; 2000 Jan; 27(1):149-54. PubMed ID: 10648031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study.
    Dziankowska-Bartkowiak B; Waszczykowska E; Łuczyńska M; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2002 Feb; 8(2):CR108-12. PubMed ID: 11859283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
    Kim WU; Min SY; Cho ML; Hong KH; Shin YJ; Park SH; Cho CS
    Arthritis Res Ther; 2005; 7(1):R71-9. PubMed ID: 15642145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
    Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
    Nishijima C; Sato S; Takehara K
    J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis.
    Sato S; Nagaoka T; Hasegawa M; Nishijima C; Takehara K
    Dermatology; 2000; 200(3):196-201. PubMed ID: 10828626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
    Mediators Inflamm; 2005 Aug; 2005(3):144-9. PubMed ID: 16106100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis.
    Yamaguchi Y; Ono J; Masuoka M; Ohta S; Izuhara K; Ikezawa Z; Aihara M; Takahashi K
    Br J Dermatol; 2013 Apr; 168(4):717-25. PubMed ID: 23110679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.
    Brown M; Postlethwaite AE; Myers LK; Hasty KA
    Clin Rheumatol; 2012 Jun; 31(6):973-81. PubMed ID: 22367096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors.
    Ciechomska M; Huigens CA; Hügle T; Stanly T; Gessner A; Griffiths B; Radstake TR; Hambleton S; O'Reilly S; van Laar JM
    Ann Rheum Dis; 2013 Aug; 72(8):1382-9. PubMed ID: 23223421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.